Research programme: interleukin-1 receptor associated kinase inhibitors - Rigel Pharmaceuticals

Drug Profile

Research programme: interleukin-1 receptor associated kinase inhibitors - Rigel Pharmaceuticals

Alternative Names: IRAK4 kinase inhibitors - Rigel Pharmaceuticals; R 191

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 07 Oct 2016 Rigel Pharmaceuticals announces intention to file an IND application with the US FDA in 2017
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Haematological malignancies presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 13 Apr 2016 Preclinical trials in Haematological malignancies in USA (unspecified route) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top